Navigation Links
Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
Date:2/4/2009

SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 11th Annual BIO CEO & Investor Conference. The details are as follows:

    Corporate Presentation:
    Date:  Monday, February 9, 2009
    Time:  3:45 p.m. - 4:15 p.m. Eastern
    Location: Waldorf Astoria, Astor Room, New York
    Speaker: Graham Cooper, Chief Financial Officer

    Panel Discussion:
    Feeding the Need for New Treatments in Obesity
    Date:  Monday, February 9, 2009
    Time:  11:00 a.m. - 12:10 p.m. Eastern
    Location: Waldorf Astoria, East Foyer, New York
    Speaker: Dr. Dennis Kim, Senior Vice President, Corporate Development

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
2. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
3. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
4. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
5. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
6. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
7. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
8. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
9. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
10. Omnitura Therapeutics Announces Private Placement Financing
11. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
Breaking Biology Technology:Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Dutch Biotech Company Pepscan Appoints New CEO 2
...ION OF VARIOUS FINANCIAL AND RESTRUCTURING ALTERNA...ire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (...rmaceutical and medical device company, today anno...anagement (Ares) and New Leaf Venture Partners (Ne...e Purchase Agreement dated July 7, 2008. Angiotech...
...GO, Nov. 21 Gen-Probe,s (Nasdaq: GPRO ),CE-mark...ecular tool to more,accurately detect high-risk hu...iated with cervical cancer or precancerous lesions...entific posters presented last week by,independent...nference of the,European Research Organization on ...
...FF LAKE, N.J., Nov. 20 Par Pharmaceutical Compani....S. District Court for the District of New Jersey ...tion for a temporary restraining order (TRO) halti...budesonide inhaled solution). In conjunction with...d and that it too would halt all sales of its auth...
Other Biology Technology:Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners 2Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners 3Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners 4Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 2Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 3Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 4Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 5Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension 2
(Date:12/4/2009)CORVALLIS, Ore. According to an analysis of statewide data taken from 1998-2001, women in Oregon who made less than $50,000 a year were more than three times likely to report they were discriminated
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/4/2009)A major discovery is challenging accepted thinking about amyloids the fibrous protein deposits associated with diseases such as Alzheimer,s and Parkinson,s and may open up a potential new area for t
Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2How to read brain activity? 2New therapy targets for amyloid disease 2Climbing to new heights in the forest canopy 9503 1Climbing to new heights in the forest canopy 9503 2Sperm Cell Insights May Aid Stem Cell Research 53867 1Wrongful Death Lawsuit for Tyler R Hill Against Ambassadors Group docleaf et al Officially Settled 53862 1Wrongful Death Lawsuit for Tyler R Hill Against Ambassadors Group docleaf et al Officially Settled 53862 2Wrongful Death Lawsuit for Tyler R Hill Against Ambassadors Group docleaf et al Officially Settled 53862 3
...cher has found that sick female deer mice devote t...isa Schwanz, a researcher in the department of eco...e size of offspring for both infected and healthy ... with a parasite produced larger offspring than he...use most mammals tend to focus on their own surviv...
... Amyloid deposits in tissues and organs are linked...rkinsons, type II diabetes, and prion diseases suc...cal substances; they have potential as a nanomater...ecular assemblies exceed those of synthetic polyme...n the journal Angewandte Chemie, since the buildin...
...ission has awarded 4.5 million to a pan-European c...opes biological data resources into a sustainable,...ciences. The European Life-science Infrastructure ... by the European Molecular Biology Laboratorys Eur...lves 32 partners from 13 countries. The consortium...
Other Biology News:Mice mothers devote energies to offspring when life is threatened 2Protein fibrils as alternative plastics? 2Securing the future of Europe's biological data resources 2
Mouse Anti-Human B-Cells (FMC7 Antigen) Monoclonal Antibody, FITC Conjugated from AbD Serotec
... boxes are ideal for use in refrigerators, freezer...arious storage racks. Four vibrant colors allow fo...n the bottom allow liquid nitrogen drainage or pro....7 mm cell) grid which holds 81 tubes. Box dimen...
Rabbit Anti-PARATHION Polyclonal Antibody, Unconjugated from AbD Serotec
Rabbit Anti-Bacterial HISTIDASE Polyclonal Antibody, Unconjugated from AbD Serotec
Biology Products: